Compare Quest Diagnostics Inc (DGX) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Oatly Group AB - ADR — how do they compare? Quest Diagnostics Inc trades at $237.3 (market cap $26.21B), while Oatly Group AB - ADR trades at $13.24 (market cap $415.98M). The key difference: Quest Diagnostics Inc is far larger — about 63× Oatly Group AB - ADR's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Oatly Group AB - ADR pays none. Which is the better fit depends on your goals.
| DGX | OTLY | |
|---|---|---|
Market Cap | $26.21B | $415.98M |
Sector | Health | Consumer Staples |
52-Week High | $238.50 | $18.54 |
52-Week Low | $173.49 | $8.03 |
Enterprise Value | $31.97B | $920.39M |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
OTLY trades at $13.18, up 0.46% on the day, with a bullish technical signal driven by moving averages and oversold RSI conditions. Revenue growth is accelerating, with Q2 2026 sales reaching $240.1 million and full-year guidance raised, though the company remains unprofitable with a net margin of -13.81%. Cash flow trends show reduced operational losses, but negative free cash flow persists.
The outlook hinges on OTLY's path to profitability; improved gross margins and cost controls offer potential upside, but high debt and sustained cash burn pose significant risks. Analyst sentiment is mixed with a 44.44% buy rating, reflecting optimism for growth against financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
